Linagliptin/Metformin Hcl Pharos (Metformin Hydrochloride, Linagliptin)

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, raising incretin hormone levels that stimulate insulin release only when glucose is high. Metformin reduces hepatic glucose production, limits intestinal absorption of glucose, and improves peripheral insulin sensitivity, together lowering blood glucose.

The specific dose and formulation are determined by the prescribing clinician based on individual factors such as renal function, glycemic targets, and concomitant medications. The prescriber will select the appropriate strength and titration schedule according to local labeling and clinical guidelines.

Safety in pregnancy and lactation has not been fully established. Linagliptin is generally avoided during pregnancy, while metformin may be used only when the potential benefit justifies the potential risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin alone, adding linagliptin provides greater HbA1c reduction without the weight gain seen with some sulfonylureas or insulin. Linagliptin is primarily excreted unchanged, allowing use without dose adjustment in mild to moderate renal impairment, unlike many other DPP‑4 inhibitors.

Store at ambient temperature below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

The tablets are taken orally, usually once daily with or without food, as directed by the prescribing clinician. Patients should swallow the tablet whole with a full glass of water and follow any specific timing instructions related to meals or other medications.

The most serious adverse events include metformin‑associated lactic acidosis, especially in patients with severe renal or hepatic impairment, and rare cases of pancreatitis linked to DPP‑4 inhibition. Prompt medical attention is required for unexplained abdominal pain, rapid breathing, or severe gastrointestinal distress.

Individuals with known hypersensitivity to linagliptin, metformin, or any excipients should avoid the product. It is also contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and those with severe hepatic disease.